ORCID as entered in ROS
https://orcid.org/0000-0003-3090-795X
Select Publications
Conference Papers
, 2014, 'BRCA1/2 MUTATIONS ASSOCIATED WITH PROGRESSION FREE SURVIVAL IN OVARIAN CANCER PATIENTS WHO RECEIVED PAZOPANIB OR PLACEBO IN THE AGO-OVAR16 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'COMPARISON OF OVARIAN AND RENAL CLEAR CELL CARCINOMA BY COMPREHENSIVE TUMOR PROFILING', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 148 - 148, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500123&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'DRY EYES & AIS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 33 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'DRY EYES & AIS', in CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, WILEY-BLACKWELL, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344530600094&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'GAMUT - GENOMIC ANALYSIS OF MUCINOUS TUMOURS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 129 - 130, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'HIGH-GRADE MUCINOUS OVARIAN CANCER: CLINICAL AND MOLECULAR ANNOTATION OF A RARE CANCER, ORIGINS AND THERAPEUTIC POTENTIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 426 - 427, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500300&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'OVARIAN CANCER SCREENING BY AUSTRALIAN WOMEN FROM FAMILIES WITH BRCA1 OR BRCA2 MUTATIONS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 223 - 224, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'PARAGON (ANZGOG0903): PHASE 2 STUDY OF ANASTROZOLE IN WOMEN WITH ESTROGEN(ER)/PROGESTERONE (PR) POSITIVE PLATINUM RESISTANT/REFRACTORY RECURRENT OVARIAN CANCER (PRROC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 38 - 38, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'PEGASUS - Prevalence and severity of genitourinary symptoms and impact on sexual function and quality of life in postmenopausal women receiving adjuvant endocrine therapy for early stage breast cancer - A prospective study', in MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, LIPPINCOTT WILLIAMS & WILKINS, DC, Washington, pp. 1364 - 1364, presented at
, 2014, 'A phase III trial of adjuvant chemotherapy following chemoradialion as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/G0G0274/RTOG1174).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2014, 'Characterization of ovarian cancer long-term responders on olaparib.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2014, 'Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2014, 'Molecular profiling of clear cell ovarian carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2014, 'The PARAGON phase 2 trial of anastrozole us women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2014, 'The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab no patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2014, 'Dry Eyes and AIs', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433199700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'QUALITY OF REPORTING OF PATIENT RATED OUTCOMES IN OVARIAN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEW', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'THE ANZUP PHASE 3 ACCELERATED BEP TRIAL: A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'BARRIERS TO RECRUITMENT FOR A POST-CANCER FATIGUE INTERVENTION STUDY - THE TOPS TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 116 - 116, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'CARING FOR WOMEN WITH OVARIAN CANCER IN THE LAST YEAR OF THEIR LIFE: IMPACT ON THE CAREGIVER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 103 - 103, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'PHYSICAL ACTIVITY (PA) PARTICIPATION FOR WOMEN WITH OVARIAN CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 114 - 114, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Psychosocial Predictors of Survival in Invasive Ovarian Cancer: A Population-Based Prospective Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 46 - 47, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'QUALITATIVE ANALYSIS OF KNOWLEDGE, ATTITUDES AND EXPERIENCES REGARDING URINARY SYMPTOMS AMONG POSTMENOPAUSAL WOMEN TAKING AROMATASE INHIBITORS FOR EARLY STAGE BREAST CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 143 - 143, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Quality of Life, Distress and Coping in Women With Ovarian Cancer: A Population Based, Longitudinal Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 44 - 44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Analyzing patient-reported outcome (PRO) endpoints in advanced cancer clinical trials: responder analysis versus mixed model for repeated measures (MMRM) illustrated with results from the AURELIA ovarian cancer trial', in QUALITY OF LIFE RESEARCH, SPRINGER, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209359000043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Mucinous ovarian tumors: Are they all the same?', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1078-0432.OVCA13-A3
, 2013, 'PHYSICAL ACTIVITY AND SLEEP DISTURBANCES FOR WOMEN WITH RECURRENT OVARIAN CANCER UNDERGOING CHEMOTHERAPY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379502010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'PROGRESSION-FREE SURVIVAL BY GCIG CRITERIA: ANALYSIS OF THE SECONDARY ENDPOINT OF THE AGO-OVAR16 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379500111&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S161 - S161, presented at
, 2013, 'Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S712 - S713, presented at
, 2013, 'Quality of life in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC) receiving either pazopanib monotherapy or placebo after first-line chemotherapy: AGO-OVAR16 results', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S713 - S713, presented at
, 2013, 'DO BRCA1 AND BRCA2 MUTATION CARRIERS HAVE EARLIER NATURAL MENOPAUSE THAN THEIR NON-CARRIER RELATIVES?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 54 - 54, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'MUCINOUS OVARIAN TUMOURS: IS ONE OF THESE THINGS NOT LIKE THE OTHERS?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'RISK-REDUCING BEHAVIOUR OF FEMALE BRCA1 AND BRCA2 MUTATION CARRIERS; LONG-TERM FOLLOW-UP OF PARTICIPANTS IN kConFab', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Olaparib monotherapy in patients with advanced cancer and a germ-line BRAC1/2 mutation: An open-label phase II study', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS12-OT2-3-07
, 2012, 'Do BRCA1 and BRCA2 mutation carriers have an earlier natural menopause than their non-carrier relatives: A study from the Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab).', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS12-P4-13-10
, 2012, 'OVARIAN CANCER PATIENTS' EXPECTATIONS OF PALLIATIVE CHEMOTHERAPY: THE FINE LINE BETWEEN HOPE AND MISUNDERSTANDING', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 244 - 244, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'QUALITY OF LIFE AND COPING IN OVARIAN CANCER: THE LAST YEAR OF LIFE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 355 - 355, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400415&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and UK phase I/II trials', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
Filter by type
https://orcid.org/0000-0003-3090-795X